ClinicalTrials.gg
CompletedNCT03053622Updated Feb 21, 2024Results posted

A Study of Mirikizumab (LY3074828) Injection in Healthy Participants

A Phase 1 interventional study of Mirikizumab Test and Mirikizumab Test in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is conducted to compare how much mirikizumab, in two different formulations, is absorbed into the bloodstream and how long the body takes to get rid of it, when given as an injection under the skin or into the veins. Side effects of the injection will be collected. Each participant will be in the study for about 18 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a screening (BMI) of greater than 18 and less than or equal to 32 kilograms per meter squared (kg/m²), inclusive
  • Have medical test results that are acceptable for the study
  • Must be willing to make oneself available for the whole study and be willing to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • Are currently participating or recently participated in a clinical trial or any other type of medical research judged to be incompatible with this study
  • Have known allergies to compounds or drugs similar to Mirikizumab
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or medical test results that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Mirikizumab Test Subcutaneous (SC) 1

    250 mg mirikizumab test formulation given as a single injection SC in healthy participants

    Biological: Mirikizumab Test

  • Experimental
    Mirikizumab Test SC 2

    250 mg mirikizumab test formulation given as two injections given SC in healthy participants

    Biological: Mirikizumab Test

  • Experimental
    Mirikizumab Test Intravenous (IV)

    250 mg mirikizumab test formulation given as an infusion into the vein in healthy participants

    Biological: Mirikizumab Test

  • Active comparator
    Mirikizumab Reference

    250 mg mirikizumab reference formulation given as three injections subcutaneous (SC) in healthy participants

    Biological: Mirikizumab Reference

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC\[0-∞\]) of Mirikizumab

    Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose

Secondary outcomes

  1. PK: Maximum Observed Concentration (Cmax) of Mirikizumab

    PK: Maximum Observed Concentration (Cmax) of Mirikizumab

    Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose

  2. PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab

    PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab

    Time frame: 0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose

07

Results

Posted Feb 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneMirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)
Started17161717
Received at least one dose of study drug17161717
Completed17161716
Not completed0001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC\[0-∞\]) of Mirikizumab

Time frame:
0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
Reported as:
Geometric mean · Microgram* Day/Milliliter(µg*day/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab
Microgram* Day/Milliliter(µg*day/mL)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC[0-∞]) of Mirikizumab215 ± 31214 ± 55293 ± 36695 ± 22
Statistical analysis
  • Mirikizumab Reference vs Mirikizumab Test SC 2 · Ratio of geometric least squares means: 0.996 · 90% CI 0.807 to 1.23
  • Mirikizumab Test SC 2 vs Mirikizumab Test SC 1 · Ratio of geometric least squares means: 0.729 · 90% CI 0.591 to 0.898
  • Mirikizumab Test SC 1 vs Mirikizumab Test Intravenous (IV) · Ratio of geometric least squares means: 0.422 · 90% CI 0.343 to 0.518
  • Mirikizumab Test SC 2 vs Mirikizumab Test Intravenous (IV) · Ratio of geometric least squares means: 0.307 · 90% CI 0.249 to 0.379
SecondaryPK: Maximum Observed Concentration (Cmax) of Mirikizumab

PK: Maximum Observed Concentration (Cmax) of Mirikizumab

Time frame:
0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
Reported as:
Geometric mean · Microgram/Milliliter (µg/mL)
PK: Maximum Observed Concentration (Cmax) of Mirikizumab
Microgram/Milliliter (µg/mL)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)
PK: Maximum Observed Concentration (Cmax) of Mirikizumab11.4 ± 3411.2 ± 5114.9 ± 3290.0 ± 14
Statistical analysis
  • Mirikizumab Reference vs Mirikizumab Test SC 2 · Ratio of geometric least squares means: 0.986 · 90% CI 0.810 to 1.20
  • Mirikizumab Test SC 2 vs Mirikizumab Test SC 1 · Ratio of geometric least squares means: 0.753 · 90% CI 0.619 to 0.916
SecondaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab

PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab

Time frame:
0,end of infusion,2,6 hours(h); 24 h; 72 h; 168 h; 240 h; 336 h; 504 h; 672 h; 1008 h; 1344 h; 1680 h; 2016 h, post dose
Reported as:
Median · Hour (h)
PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab
Hour (h)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)
PK: Time of Maximum Observed Drug Concentration (Tmax) of Mirikizumab73.12 (72.45 to 145.82)73.41 (72.67 to 240.67)73.25 (72.22 to 145.30)2.00 (0.50 to 2.15)
Statistical analysis
  • Mirikizumab Reference vs Mirikizumab Test SC 2 · Median difference (final values): 0.28 · 90% CI -0.10 to 48.40
  • Mirikizumab Test SC 2 vs Mirikizumab Test SC 1 · Median difference (final values): 0.25 · 90% CI -0.25 to 23.97In this outcome, the median difference is not calculated by subtracting two observations, it is derived by "Hodges-Lehmann approach to estimating location shift". This method will give the value of 0.25.

Adverse events

Collected over Up To 4 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mirikizumab Reference0/17 (0%)0/17 (0%)17/17 (100%)
Mirikizumab Test SC 20/16 (0%)0/16 (0%)15/16 (93.8%)
Mirikizumab Test SC 10/17 (0%)0/17 (0%)17/17 (100%)
Mirikizumab Test Intravenous (IV)0/17 (0%)0/17 (0%)15/17 (88.2%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventMirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)
Injection site reactionGeneral disorders17/1715/1617/170/17
NasopharyngitisInfections and infestations5/172/161/177/17
HeadacheNervous system disorders2/172/162/174/17
Abdominal pain upperGastrointestinal disorders2/170/160/170/17
DiarrhoeaGastrointestinal disorders1/171/162/170/17
Injection site bruisingGeneral disorders2/170/160/170/17
PalpitationsCardiac disorders0/171/160/170/17
Ear painEar and labyrinth disorders0/171/160/170/17
Abdominal discomfortGastrointestinal disorders0/171/160/170/17
Abdominal distensionGastrointestinal disorders1/171/160/170/17

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)Total
Mean44.7 ± 13.340.7 ± 18.052.1 ± 9.643.6 ± 14.945.4 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)Total
Female659828
Male11118939
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)Total
Hispanic or Latino00022
Not Hispanic or Latino1716171565
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American02013
White1713171663
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Mirikizumab ReferenceMirikizumab Test SC 2Mirikizumab Test SC 1Mirikizumab Test Intravenous (IV)Total
United Kingdom1716171767
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Apr 2018, 11 months.

Results were first posted in Feb 2024, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2017
First posted
Feb 15, 2017
StartActual
Apr 24, 2017
Primary completionActual
Apr 3, 2018
CompletionActual
Apr 3, 2018
Results first posted
Feb 21, 2024
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03053622
Responsible party
Sponsor
First posted
Feb 15, 2017
Start date
Apr 24, 2017
Primary completion
Apr 3, 2018
Completion
Apr 3, 2018
Results posted
Feb 21, 2024
Last update
Feb 21, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion